BioCentury | Dec 12, 2011
Company News

OvaGene Oncology, H. Lee Moffitt Cancer Center deal

...by assays for a variety of gynecologic cancers and other tumors. Details were not disclosed. OvaGene Oncology...
BioCentury | Jul 26, 2010
Company News

OvaGene Oncology, Inven 2 AS deal

...tests to its CLIA lab over the next 12-18 months. Further terms were not disclosed. OvaGene Oncology...
BioCentury | Jul 26, 2010
Company News

OvaGene Oncology, University of Bergen deal

...early-stage endometrial cancer patients linked with high risk of recurrence. Financial terms were not disclosed. OvaGene Oncology...
Items per page:
1 - 3 of 3
BioCentury | Dec 12, 2011
Company News

OvaGene Oncology, H. Lee Moffitt Cancer Center deal

...by assays for a variety of gynecologic cancers and other tumors. Details were not disclosed. OvaGene Oncology...
BioCentury | Jul 26, 2010
Company News

OvaGene Oncology, Inven 2 AS deal

...tests to its CLIA lab over the next 12-18 months. Further terms were not disclosed. OvaGene Oncology...
BioCentury | Jul 26, 2010
Company News

OvaGene Oncology, University of Bergen deal

...early-stage endometrial cancer patients linked with high risk of recurrence. Financial terms were not disclosed. OvaGene Oncology...
Items per page:
1 - 3 of 3